Keeping Track: Opana ER Abuse Deterrence Claim Withdrawn; Third Neulasta Biosimilar Submitted; Keytruda Cleared In Head And Neck Cancer

 
• By Bridget Silverman

The latest drug development news and highlights from our FDA Performance Tracker.

More from United States

More from North America